Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPAMAAST dapagliflozin crossover study in type 2 diabetes
NL-OMON46385Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Skeletal muscle insulin sensitivity. Started Mar 2018; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON46385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46385.